Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma

Pastor, María A.; Dy, Carlos; Alegria, E.; Aparicio, Luís M. Antón; Â, Gil; Harguindey, Salvador; Jl, Zubieta; Lage, Mary

doi:10.1097/00000421-198506000-00002

Cited by 11 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our interest in the treatment of malignant gliomas (MG), mainly glioblastoma multiforme (GBM), dates from more than thirty years ago [1], and interest in the relationship of pH and cancer dates even further back to a decade earlier [2]. In order to describe the new pH-centric approach to malignant diseases, the concept of “hydrogen ion dynamics of cancer” was introduced in the early 1980s [3], a term that is increasingly used in publications in this growing field in cancer research and treatment [4].…”

Section: Introductionmentioning

confidence: 99%

Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies

Harguindey¹,

Orozco²,

Alfarouk

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

The treatment of cancer has been slowly but steadily progressing during the last fifty years. Some tumors with a high mortality in the past are curable nowadays. However, there is one striking exception: glioblastoma multiforme. No real breakthrough has been hitherto achieved with this tumor with ominous prognosis and very short survival. Glioblastomas, being highly glycolytic malignancies are strongly pH-dependent and driven by the sodium hydrogen exchanger 1 (NHE1) and other proton (H+) transporters. Therefore, this is one of those pathologies where the lessons recently learnt from the new pH-centered anticancer paradigm may soon bring a promising change to treatment. This contribution will discuss how the pH-centric molecular, biochemical and metabolic perspective may introduce some urgently needed and integral novel treatments. Such a prospective therapeutic approach for malignant brain tumors is developed here, either to be used alone or in combination with more standard therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies

Harguindey¹,

Orozco²,

Alfarouk

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

Adjuvant intraarterial chemotherapy with nimustine in the management of world health organization grade IV gliomas of the brain. Experience at the department of neurosurgery of Düsseldorf university

Roosen

Kiwit

Lins

et al. 1989

Cancer

View full text Add to dashboard Cite

A protocol with postoperative adjuvant intraarterial (ia) chemotherapy using nimustine (ACNU) was followed at the University of Dusseldorf (Federal Republic of Germany) after histologic confirmation of malignant glioma of the brain. The first iaACNU procedure was performed within 10 days of surgery, and immediately before postoperative irradiation. After radiotherapy further iaACNU courses were given. The study population consisted of 35 primarily treated malignant gliomas World Health Organization (WHO) Grade IV, i.e., glioblastomas (NIv). Of these tumors 11 showed early progressive disease (PD) (NIV whereas 24 had stable or responsive disease (Nlv SDBm). Seven patients with recurrent malignant gliomas W H O Grade IV (NIv recurrent) were also treated plus six patients with malignant gliomas W H O Grade 111 (NIlr). Experience with 50 treated patients resulted from this study. The median survival time (MST) for the group NIV was 14.2 months; 41.0% of patients were long-term survivors. The MST for the group NIv primPD was 7.8 months; 9.1% of patients were long-term survivors. For the group NIv sDaRD a M S T of 18.3 months and 66.7% of long-term survivors were determined. Patients with recurrent tumors on this treatment protocol had an additional MST of 6.1 months. The total M S T after first surgery was 16.2 months. The incidence of complications was low. Systemic complications were infrequent or rare. Retinal disturbances were seen in two patients; leukoencephalopathy was not seen in our patients. In 10% of patients cerebral complications were found, which were irreversible in 2% of patients. Complications could not be assigned unequivocally to the nitrosourea. These results compare favorably with what is reported in the literature, demonstrate the potential value of iaACNU in the treatment of malignant gliomas W H O Grade IV, and should encourage the initiation of a randomized clinical trial of adjuvant iaACNU in the therapy of these tumors. The authors propose iaACNU as a valuable approach in the management of primarily diagnosed malignant gliomas W H O Grade IV, but cannot recommend the delay of iaACNU until the recurrence of a brain tumor. Cancer 64:1984-1994, 1989. HE PROGNOSIS for patients with malignant gliomas large randomized controlled clinical trials by the Brain T of the brain is still very poor, despite intensive basic Tumor Study Group (BTSG).7.8 These same studies iis and clinical research on the treatment of these tu-well as others showed a positive effect of chemotherapy mors.Ie4 The mainstay of the management of malignant on the course of the disease too, although the increase in cerebral gliomas certainly is surgical excision and post-median survival time (MST) and in the proportion of operative r a d i ~ t h e r a p y. ~ ~ ~ This has been demonstrated in long-term survivors remained relatively m o d e ~ t. ~-~ Other

show abstract

Intraarterial Chemotherapy for Brain Tumors: A Summary of the Ottawa Experience

Stewart

1987

Brain Oncology Biology, Diagnosis and Therapy

View full text Add to dashboard Cite

Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma

Cited by 11 publications

References 0 publications

Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies

Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies

Adjuvant intraarterial chemotherapy with nimustine in the management of world health organization grade IV gliomas of the brain. Experience at the department of neurosurgery of Düsseldorf university

Intraarterial Chemotherapy for Brain Tumors: A Summary of the Ottawa Experience

Contact Info

Product

Resources

About